Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions

Neoadjuvant chemotherapy (NACT) can change invasive breast carcinomas (IBC) and influence the patients' overall survival time (OS). We aimed to identify IBC changes after NACT and their association with OS. IBC data in pre- and post-NACT samples of 86 patients were evaluated and associated with...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research and treatment Vol. 56; no. 1; pp. 178 - 190
Main Authors:	Jaime Dos Santos, Bárbara, Balabram, Débora, Mara Reis Gomes, Virginia, Costa Café de Castro, Carolina, Henrique Costa Diniz, Paulo, Araújo Buzelin, Marcelo, Buzelin Nunes, Cristiana
Format:	Journal Article
Language:	English
Published:	Korea (South) Korean Cancer Association 01-01-2024 대한암학회
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast Neoplasms - pathology Chemotherapy, Adjuvant Female Humans Ki-67 Antigen Neoadjuvant Therapy Neoplasm Grading Original Prognosis Receptor, ErbB-2 - metabolism 의학일반 Ki-67 antigen Neoadjuvant therapy Tumor-infiltrating lymphocytes Estrogen receptors Breast neoplasms ErbB-2 receptor Progesterone receptors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Neoadjuvant chemotherapy (NACT) can change invasive breast carcinomas (IBC) and influence the patients' overall survival time (OS). We aimed to identify IBC changes after NACT and their association with OS. IBC data in pre- and post-NACT samples of 86 patients were evaluated and associated with OS. Post-NACT tumors changed nuclear pleomorphism score (p=0.025); mitotic count (p=0.002); % of tumor-infiltrating inflammatory cells (p=0.016); presence of in situ carcinoma (p=0.001) and lymphovascular invasion (LVI; p=0.002); expression of estrogen (p=0.003), progesterone receptors (PR; p=0.019), and Ki67 (p=0.003). Immunohistochemical (IHC) profile changed in 26 tumors (30.2%, p=0.050). Higher risk of death was significatively associated with initial tumor histological grade III (hazard ratio [HR], 2.94), high nuclear pleomorphism (HR, 2.53), high Ki67 index (HR, 2.47), post-NACT presence of LVI (HR, 1.90), luminal B-like profile (HR, 2.58), pre- (HR, 2.26) and post-NACT intermediate mitotic count (HR, 2.12), pre- (HR, 4.45) and post-NACT triple-negative IHC profile (HR, 4.52). On the other hand, lower risk of death was significative associated with pre- (HR, 0.35) and post-NACT (HR, 0.39) estrogen receptor-positive, and pre- (HR, 0.37) and post-NACT (HR, 0.57) PR-positive. Changes in IHC profile were associated with longer OS (p=0.050). In multivariate analysis, pre-NACT grade III tumors and pre-NACT and post-NACT triple negative IHC profile proved to be independent factors for shorter OS. NACT can change tumor characteristics and biomarkers and impact on OS; therefore, they should be reassessed on residual samples to improve therapeutic decisions.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1598-2998 2005-9256 2005-9256
DOI:	10.4143/crt.2023.386